ArticleBMC nephrology2025
Sarcopenia is associated with mortality among newly initiated peritoneal dialysis patients with end-stage kidney disease: a longitudinal follow-up study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectiveData regarding to how muscle mass and function affect mortality in newly initiated peritoneal dialysis (PD) patients have led to inconclusive results. The goal of this research was to determine the relationship between sarcopenia and the risk of mortality among end-stage kidney disease (ESKD) patients who were newly initiated on PD.
methodsPatients were prospectively recruited among newly initiated PD patients with ESKD, and followed up at regular intervals from January 2021 to June 2024. The status of sarcopenia in the baseline visit was the exposure of interest. The death event during the follow-up period was the primary outcome. Kaplan-Meier analysis with log-rank test was used to compare overall survival between groups. Confounders were adjusted by employing Cox proportional hazards models.
results298 eligible participants were included for the final statistical analysis. Among these 298 participants, the prevalence of sarcopenia was 40.9% (122), of which the prevalence of non-severe sarcopenia was 22.1% (66) and that of severe sarcopenia was 18.8% (56). During the 6730 person-months of follow-up (median 25 months, maximum 42 months), 22.1% (66) participants died. Of these, 30.3% (37) were in the group with sarcopenia and 16.5% (29) were in the group with non-sarcopenia, with an absolute difference of 13.8% (95%CI 4.0%-23.6%). The Kaplan-Meier survival curve revealed that the participants with sarcopenia had a poorer survival rate compared to those without sarcopenia (Log-rank test, χ
conclusionOur study demonstrated that the status of sarcopenia was significantly associated with an increased risk of mortality in ESKD patients who newly initiated PD, especially in elderly individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.